About this episode

CMI Communications editors discuss significant findings in infectious diseases from the second quarter of 2026.

In the second edition of 'Quarterly catch-up', CMI Communications editors Emily McDonald and Erin McCreary round-up the biggest news in infectious diseases and review clinical microbiology and infectious diseases studies published in the second quarter of 2026 [1-4]. From Pneumocystis jirovecii pneumonia in solid-organ-transplant recipients to a double-blind randomised controlled trial reporting a new antibiotic for complicated urinary tract infections, Erin and Emily highlight four articles they found particularly noteworthy, and comment on whether the results can and should change clinical practice. References Alanio A, et al. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a prospective observational cohort study, J Infect 2026. DOI: 10.1016/j.jinf.2026.106794 Ramendra R, et al. Procalcitonin to guide 7 versus 14 days of antibiotics in bloodstream infections: a secondary analysis of the BALANCE trial, JAMA Netw Open 2026. DOI: 10.1001/jamanetworkopen.2026.20973 Pai MP, et al. Challenging weight-tiered antibiotic prophylaxis in obese patients undergoing colorectal surgery using CT-derived body composition, CID 2026. DOI: 10.1093/cid/ciag383 Takahashi S…

People in this episode

Hosts: Emily McDonald, Erin McCreary

Topics covered

• infectious diseases
• clinical microbiology
• antibiotic research
• clinical practice
• medical studies

Keywords

• infectious diseases
• clinical microbiology
• antibiotics
• Pneumocystis jirovecii pneumonia
• urinary tract infections

Mentioned in this episode

Organizations: CMI Communications

Books & works: Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a prospective observational cohort study, Procalcitonin to guide 7 versus 14 days of antibiotics in bloodstream infections: a secondary analysis of the BALANCE trial, Challenging weight-tiered antibiotic prophylaxis in obese patients undergoing colorectal surgery using CT-derived body composition, Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial

More episodes of Communicable

• Communicable E62: The 'prose' and cons of the POET trial – early oral antibiotic switch for endocarditis · September 6, 2026 · 52 min
• Communicable E61: We will make you love PK/PD, part 3 · August 23, 2026 · 53 min
• Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain · July 26, 2026 · 1h 9m
• Communicable E58: Reducing hospital-acquired pneumonia – the HAPPEN trial and how it happened · July 12, 2026 · 54 min
• Communicable E57: We will make you love PK/PD, part 2 · June 28, 2026 · 47 min
• Communicable E56: Frequentist vs Bayesian for clinical trial analysis – 99% probability you’ll want to listen to this · June 14, 2026 · 1h 5m

Explore listener stats, chart rankings, contacts and more on the Communicable podcast page.